Medical Department 1
1. Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs
2. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
3. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
4. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
5. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
6. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
7. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
8. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs
9. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs
10. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs
11. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs
12. The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country Multidrug-Resistant/ Rifampicin-Resistant Tuberculosis Cohort
13. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis
14. Overcoming Barriers in Hospital-Based Health Technology Assessment (HB-HTA): International Expert Panel Consensus
15. The monkeypox virus: A public health challenge threatening Africa
16. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)
17. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
18. Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin
19. Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
20. Work at high altitude and non-fatal cardiovascular disease associated with unfitness to work: Prospective cohort observation
21. Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB
22. Effectiveness of a bedaquiline, linezolid, clofazimine ‘core’ for multidrug-resistant TB
1